Name: UMIN ID:
Unique ID issued by UMIN | UMIN000021560 |
---|---|
Receipt number | R000024772 |
Scientific Title | A study to evaluate the relation between the efficacy and early Immune Related Advers Events of Nivolmab in patients with non-small cell lung cancer |
Date of disclosure of the study information | 2016/03/24 |
Last modified on | 2023/03/08 19:02:04 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2016/03/22 13:56:10 | ||
2 | Update | 2016/03/25 18:43:38 | Recruitment status |
|
3 | Update | 2016/03/25 18:46:12 | UMIN ID1 |
|
4 | Update | 2016/03/25 18:47:38 | Primary outcomes Primary outcomes Key secondary outcomes Key secondary outcomes |
|
5 | Update | 2016/04/26 12:07:05 | Other related information Other related information |
|
6 | Update | 2016/04/26 12:09:21 | Other related information |
|
7 | Update | 2017/04/28 22:00:46 | Name of primary person or sponsor Organization |
|
8 | Update | 2017/09/23 13:25:10 | Last follow-up date |
|
9 | Update | 2018/04/08 17:46:30 | Recruitment status |
|
10 | Update | 2018/09/23 14:47:18 | Publication of results URL related to results and publications |
|
11 | Update | 2023/03/08 18:48:54 | Recruitment status Date of IRB |
|
12 | Update | 2023/03/08 18:51:32 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
13 | Update | 2023/03/08 19:02:04 | URL releasing protocol Publication of results Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |